The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.515
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.07 (4.73%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.515
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing of Shares & admission to Official List LSE

9 Nov 2015 07:00

RNS Number : 9302E
Silver Falcon PLC
09 November 2015
 

9th November 2015

 

Silver Falcon PLC

(the "Company")

 

Placing of 43,300,000 Ordinary Shares and admission to the Official List of the London Stock Exchange.

 

Silver Falcon PLC (LSE: SILF) today announces the successful, oversubscribed placing of 43,300,000 Ordinary Shares at a placing price of £0.03 per New Ordinary Share and admission to the Official List of the London Stock Exchange of 64,900,000 Ordinary Shares and to trading on the London Stock Exchange's main market for listed securities.

 

The Company has been formed for the purpose of acquiring a company or business. The Company's efforts in identifying a prospective target company or business will not be limited to a particular industry or geographic region, but the Directors intend to focus on the Financial Services sector and more specifically the FinTech sector in seeking acquisition targets, given their significant experience.

 

The Directors of the Company are Geoffrey Dart, Peter Redmond and Adrian Beeston, a highly knowledgeable and experienced group of professionals with extensive experience of making successful international acquisitions and the ability to return value to investors and introduce and complete operational improvements to companies.

 

It is expected that Admission will become effective and that unconditional dealings will commence at 8.00 a.m. on 9 November 2015.

 

Geoffrey Dart, Chairman, commented:

"Silver Falcon has been formed for the purpose of making acquisitions in the Financial Services Sector. Our Directors have significant track records in sourcing and executing successful acquisitions and returning value to shareholders and have a particular interest in the FinTech sub-sector. We look forward to acquiring companies that generate value for our shareholders through operational improvements, along with potential further complementary acquisitions.

 

"We are delighted that the placing was oversubscribed which indicates the confidence placed in the future of the company."

 

 

 

Ends

 

 

For more information contact:

 

Silver Falcon PLC Tel: +44 (0) 20 3757 4980

Geoffrey Dart C/O Camarco

 

Camarco Tel: +44 (0) 20 3757 4980

Billy Clegg/ Jennifer Renwick

 

 

 

 

 

Notes to Editors

 

Shareholders

Major Shareholders of the Company as at Admission are:

 

Shareholder

No. of Ordinary Shares

Percentage of issued ordinary share capital

Optiva Securities Limited (1)

5,000,000

7.70

Geoffrey Dart (2)

4,800,000

7.39

Peter Redmond (3)

3,600,000

5.54

Adrian Beeston

3,350,000

5.16

 

 

(1) Optiva Securities Limited holds these shares through JIM Nominees Limited.

(2) Geoffrey Dart holds 2,300,000 shares through Chesterfield Capital Limited, of which he is the ultimate beneficial owner and 2,500,000 shares through Black Eagle Capital, of which he holds 45.25 per cent.

(3) Peter Redmond holds these shares through Catalyst Corporate Consultants Limited, a company of which he is the sole shareholder.

 

Directors

Geoffrey Dart

Geoffrey Dart is a merchant banker with over 35 years of experience of fund raising and listing transactions. In 1990 he was appointed to the board of Harrell Hospitality Inc, a hotel management and development company, after he structured and completed its reverse takeover by a US-listed shell company. In 2003, as chairman of Energy Technique Plc (a Main Market company) Geoffrey oversaw the re-structuring and re-capitalisation of the company. Also in 2003, as a founder and an executive director of London and Boston Investments Plc (an AIM-listed company), Geoffrey was responsible for M&A activity for the company. In 2010, Geoffrey joined the board of Hayward Tyler Limited, the specialist pump manufacturer and after raising equity and debt funding, completed the Main Market listing of the company and thereafter took on particular responsibility for the group's Chinese operations and completed a successful re-structuring of those operations.

 

Peter Redmond

Peter Redmond is a corporate financier with some 30 years' experience in corporate finance and venture capital. He has acted on and assisted a wide range of companies to attain a listing over many years, on the Unlisted Securities Market, the Full List and AIM, whether by IPO or in many cases via reversals, across a wide range of sectors, ranging from technology through financial services to natural resources and, in recent years has done so as a director of the companies concerned. He has been active over many years in corporate rescues and reconstructions on AIM and in reverse transactions into a range of investing companies. He was a founder director of Cleeve Capital plc (now Satellite Solutions Worldwide Group plc) and Mithril Capital plc, both of which were admitted to the Standard List of the London Stock Exchange, and took a leading role in the reconstruction and refinancing of AIM-quoted Kennedy Investments and 3Legs Resources plc.

 

Adrian Richard Thorpe Beeston

Adrian founded Thorpe-Beeston Investments Ltd ("TBIL") in 2002. TBIL specializes in the financing and structuring of small to medium size businesses, and the flotation of these companies on the American Stock Exchange, AIM Exchange and TSX Venture Exchange. Previous to this, Adrian was at Altium Capital, a major pan-European corporate finance house, where he focused primarily on the raising of private equity. Adrian has worked extensively in small to mid size businesses, financing and working with over 20 companies in the last 5 years. Other work has included implementation of corporate structure, human resources planning, corporate governance policies and providing finance once these cornerstones of a business are in place.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMGMVVNGKZM
Date   Source Headline
18th Nov 202211:05 amRNSSecond Price Monitoring Extn
18th Nov 202211:00 amRNSPrice Monitoring Extension
27th Oct 20224:40 pmRNSSecond Price Monitoring Extn
27th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Oct 20222:05 pmRNSSecond Price Monitoring Extn
27th Oct 20222:00 pmRNSPrice Monitoring Extension
29th Sep 20228:00 amRNSHalf-year Report
1st Sep 20228:45 amRNSPresentation at H.C. Wainwright Global Conference
22nd Aug 20227:00 amRNSAppointment of Director of Quality
15th Aug 20227:00 amRNSApproval and Issuance of Antibody Patent
10th Aug 20227:00 amRNSAppointment of Medical Director
9th Aug 20222:06 pmRNSSecond Price Monitoring Extn
9th Aug 20222:00 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSNew Custom R&D Facility Opening
8th Jul 202212:25 pmRNSInvestor Webinar Recording
1st Jul 202212:19 pmRNSChange of Registered Office
30th Jun 20223:29 pmRNSResult of Annual General Meeting
27th Jun 20227:00 amRNSInvestor Webinar
7th Jun 20222:17 pmRNSPosting of Annual Report & Notice of AGM
30th May 20227:00 amRNSDirector/PDMR Shareholding
27th May 20222:05 pmRNSSecond Price Monitoring Extn
27th May 20222:00 pmRNSPrice Monitoring Extension
16th May 20227:00 amRNSImmuno-Oncology Summit Europe Presentation
29th Apr 20225:39 pmRNSFinal Results for the Year Ended 31 December 2021
21st Mar 20224:42 pmRNSSecond Price Monitoring Extn
21st Mar 20224:36 pmRNSPrice Monitoring Extension
21st Mar 20222:06 pmRNSSecond Price Monitoring Extn
21st Mar 20222:01 pmRNSPrice Monitoring Extension
16th Mar 20227:00 amRNSCBR Update
4th Mar 20222:05 pmRNSSecond Price Monitoring Extn
4th Mar 20222:00 pmRNSPrice Monitoring Extension
4th Mar 202211:05 amRNSSecond Price Monitoring Extn
4th Mar 202211:00 amRNSPrice Monitoring Extension
16th Feb 20227:00 amRNSHEMO-CAR-T pre-IND Meeting Request
12th Jan 20227:00 amRNSHemogenyx Pharmaceuticals Partnership with Selexis
5th Jan 20227:00 amRNSH.C. Wainwright Bioconnect Conference
22nd Dec 20212:05 pmRNSSecond Price Monitoring Extn
22nd Dec 20212:00 pmRNSPrice Monitoring Extension
22nd Dec 202111:06 amRNSSecond Price Monitoring Extn
22nd Dec 202111:01 amRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSHemo-CAR-T partnership with WuXi ATU
13th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20218:55 amRNSHEMO-CAR-T pre-IND Meeting Request
24th Nov 20212:38 pmRNSConvertible Loans Repayment
18th Oct 20217:00 amRNSLease of New York Mink Building Custom Laboratory
13th Oct 20218:30 amRNSCDX Licence Agreement
12th Oct 20214:41 pmRNSSecond Price Monitoring Extn
12th Oct 20214:36 pmRNSPrice Monitoring Extension
30th Sep 20218:00 amRNSHalf-year Report
2nd Sep 20217:00 amRNSU.S. Approval of Monoclonal Antibody Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.